Merck KGaA, and SpringWorks Therapeutics, Inc. (SWTX) announced they have entered into a definitive agreement for Merck KGaA to acquire SpringWorks. The purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion. Merck KGaA said, upon closing, the business combination will immediately contribute to revenues and is expected to be accretive to earnings per share pre in 2027.
SpringWorks Therapeutics is a U.S. biopharmaceutical company with a systemic standard-of-care therapy in adults with desmoid tumors and the first and only approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.